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Zygomycetes are being increasingly recognized as important
opportunistic pathogens in immunocompromised hosts, espe-
cially diabetics, haematological patients, and transplant recipi-
ents. Recent reports have indicated an increase in the
incidence of zygomycosis in cancer centres in both Europe
and the USA. Cases can be either sporadic or, in the hospital
setting, related to outbreaks. Zygomycetes are found in a
wide variety of habitats, and their life cycles differ accordingly.
The rapid growth of these fungi and their widespread dispersal
in the environment undoubtedly mean that most individuals
come into regular contact with these organisms. In susceptible
hosts, the infections—including rhinocerebral, pulmonary and
disseminated disease—can be devastating and cause high rates
of morbidity and mortality. Conﬂicting data exist with regard
to the contribution of newer antifungal agents, such as vorico-
nazole, as risk factors for zygomycosis. Although survival rates
have improved, outcomes in patients with zygomycosis remain
suboptimal. Combination antifungal therapies, as well as
unique interactions of calcineurin inhibitor immunosuppres-
sive agents with antifungals, have potentially relevant implica-
tions for optimizing outcomes in cases of zygomycosis.
There are still many unresolved issues regarding the epi-
demiology, diagnosis and treatment of zygomycosis. New
aetiological agents are being reported from hitherto
unknown ecological niches, molecular diagnostic methods
have been developed, and new antifungal treatment modali-
ties have been explored in animal models and patients. Lipo-
somal amphotericin B has been used extensively for these
infections, and the role of posaconazole is being assessed. A
greater understanding of the role of iron in the pathogenesis
of zygomycosis has led to the development of iron chelation
therapy as adjunctive treatment.
The survey of zygomycosis in Europe undertaken by a
European Confederation of Medical Mycology (ECMM)
Working Group, with support from Gilead Sciences (Eur-
ope) Ltd, has contributed useful data to our understanding
of many aspects of the disease, and is the ﬁrst large pro-
spective epidemiological study to be undertaken. The wide
interest in this exercise suggested the creation of a series
of symposia to address current issues regarding zygomyco-
sis. The Hellenic Society of Medical Mycology, under the
auspices of the ECMM, organized the 1st International
Forum on Zygomycosis, supported by an unrestricted edu-
cational grant from Gilead Sciences (Europe) Ltd. A group
of investigators and clinicians from Europe and the USA,
including infectious diseases specialists, haematologists, mi-
crobiologists, and surgeons, gathered together at the end of
May 2008 and debated a diverse range of topics. Themes
included the biology of the Zygomycetes; recent trends in
epidemiology, risk factors and pathogenesis; the broadening
range of clinical presentations; diagnosis; and, treatment.
Our intention is to bring together in this supplement of
Clinical Microbiology and Infection our current knowledge and
understanding of what appears to be an emerging fungal
infection.
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